Clinical trials: Infantile Respiratory Distress Syndrome
COVID-19 Acute Respiratory Distress Syndrome, Influenza A
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
To investigate the safety and tolerance of a single infusion of ProTrans® in subjects with "severe" respiratory complications associated with pneumonia caused by COVID-19, Influenza A, Metapneumovirus or RSV infection.
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Influenza A, Metapneumovirus Pneumonia, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT04896853
- Testing
- ProTrans®
- Where
- Sweden
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NextCell Pharma Ab
Acute Respiratory Distress Syndrome
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).
- Trial name
- NCT04804943
- Testing
- NOA-001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy.
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral
- Trial name
- NCT05123755
- Testing
- AV-001 Injection
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vasomune Therapeutics, Inc.
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
- Trial name
- TILIA (NCT05624450)
- Testing
- Tozorakimab
- Where
- 473 sites in United States, Argentina and 37 more
- Volunteers
- 3,527 people
- Sponsor
- AstraZeneca
COVID-19, ARDS
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS
This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part is an open-label, single-arm, dose-escalating study to evaluate the safety and explore the dose limiting toxicity and maximum tolerated dose of…
- Conditions
- COVID-19, ARDS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04452097
- Testing
- Human umbilical cord mesenchymal stem cells + best supportive care
- Sponsor
- Baylx Inc.
COVID-19
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
- Trial name
- NCT04315298
- Testing
- Sarilumab
- Where
- 62 sites in United States
- Volunteers
- 1,912 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Respiratory Distress Syndrome
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress…
- Trial name
- NCT04502433
- Testing
- CUROSURF® (poractant alfa)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
ARDS, Human, Covid-19
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19
This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days…
- Trial name
- NCT04456361
- Testing
- Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords
- Where
- Mexico
- Volunteers
- 9 people
- Sponsor
- Instituto de Medicina Regenerativa
Altered Mental Status, Sepsis
Pre-hospital Ventilation Clinical Study
This study will collect and characterize ventilator use during patient care with a ZOLL 731 Series ventilator in a pre-hospital setting.
- Conditions
- Altered Mental Status, Sepsis, Heart Failure, Hemorrhage
- Trial name
- NCT05604430
- Testing
- 731 Series Ventilator
- Where
- 5 sites in United States
- Volunteers
- 500 people
- Sponsor
- Zoll Medical Corporation
Acute Respiratory Distress Syndrome, COVID-19
Predictors of Severe COVID-19 Outcomes
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes…
- Trial name
- PRESCO (NCT04388813)
- Where
- 8 sites in United States
- Volunteers
- 494 people
- Sponsor
- Verily Life Sciences LLC
Acute Respiratory Distress Syndrome (ARDS), Post Intensive Care Syndrome (PICS)
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied.
- Trial name
- SeeMe Tool (NCT06272942)
- Testing
- An ICU admission and a temporally related ARDS diagnosis
- Where
- United States
- Volunteers
- 640,058 people
- Sponsor
- Bayer
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Respiratory Distress Syndrome (Neonatal), Intubation Complication
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated…
- Conditions
- Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
- Trial name
- Aero-05 (NCT05960929)
- Testing
- Infasurf Aero™
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- ONY
Acute Respiratory Failure, Coma
EASiVENT Study Comparing INTELLiVENT-ASV vs Non Automated Ventilation in Adult ICU Patients
The purpose of the study is to assess the safety and efficacy of INTELLiVENT-ASV (Adaptive Support Ventilation) in adult ICU patients comparing to non automated ventilation.
- Conditions
- Acute Respiratory Failure, Coma, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT04400643
- Testing
- INTELLiVENT-ASV, Non-automated ventilation
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Hamilton Medical AG
COVID-19, Acute Respiratory Distress Syndrome
Tolerability and Efficacy of RJX in Patients With COVID-19
This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in patients with COVID-19.
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
- Trial name
- RJX (NCT04708340)
- Testing
- Rejuveinix (RJX) Active Comparator
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Reven Pharmaceuticals, Inc.
Respiratory Distress Syndrome, Newborn
Infant Respiratory Interface and Accessories Evaluation Study
Determine the usability of an interface and its accessories to provide non-invasive respiratory therapy to neonates and infants.
- Trial name
- NCT05719298
- Testing
- Respiratory interface
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- Fisher and Paykel Healthcare
Acute Respiratory Distress Syndrome
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare…
- Trial name
- NCT04390152
- Testing
- Wharton's jelly derived Mesenchymal stem cells.
- Where
- 2 sites in Colombia
- Volunteers
- 6 people
- Sponsor
- BioXcellerator
AKI, ARDS
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
Selective Cytopheretic Device (SCD) treatments will improve survival in patients testing positive for COVID-19 infection diagnosed with Acute Kidney Injury (AKI) or ARDS.
- Conditions
- AKI, ARDS, COVID
- Trial name
- NCT04395911
- Testing
- SCD
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- SeaStar Medical
Acute Respiratory Distress Syndrome
A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome
Primary Objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Secondary Objectives: To explore the…
- Trial name
- ARDS (NCT07413978)
- Testing
- 1 vial containing a total of 5×10^7 cells, 2 vial containing a total of 1×10^8 cells, 3 vial containing a total of 1.5×10^8 cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changchun Tuohua Pharmaceutical Co., Ltd.